Production of novel recombinant anti-EpCAM antibody as targeted therapy for breast cancer
International Immunopharmacology · 2023
DOI: 10.1016/j.intimp.2023.110656 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023. Verfasst von Roya Mirzaei und 9 weiteren Autor:innen. Beteiligte Einrichtung: Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran. Hauptthemen laut MEDLINE: Cell Adhesion Molecules, Breast Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 63 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The utilization of monoclonal antibodies (moAbs), an issue correlated with the biopharmaceutical professions, is developing and maturing. Coordinated with this conception, we produced the appealingly modeled anti-EpCAM scFv for breast cancer tumors. METHODS: Afterward cloning and expression of recombinant antibody in Escherichia coli bacteria, the correctness of the desired antibody was checked by western blotting. Flow cytometry was utilized to determine the capacity of the recombinant antibody to append to the desired receptors in the malignant breast cancer (BC)cell line. The recombinant antibody (anti-EpCAM scFv) was examined for preclinical efficacy in reducing tumor growth, angiogenesis, and invasiveness (in vitro- in vivo). FINDINGS: A target antibody-mediated attenuation of migration and invasion in the examined cancer cell lines was substantiated (P-value < 0.05). Grafted tumors from breast cancer in mice indicated significant and compelling suppression of tumor growth and decrement in blood supply in reaction to the recombinant anti-EpCAM intervention. Evaluations of immunohistochemical and histopathological findings revealed an enhanced response rate to the treatment. CONCLUSION: The desired anti-EpCAM scFv can be a therapeutic tool to reduce invasion and proliferation in malignant breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran.
- Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran; Department of Surgery and Radiology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
- Cancer Biology Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Surgery and Radiology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.
- Recombinant Proteins Department, Breast Cancer Research Center, Motamed Cancer Institute, ACECR, Tehran, Iran. Electronic address: laylafarahmand@gmail.com.
Zitieren
APA
Mirzaei, R., Shafiee, S., Vafaei, R., Salehi, M., Jalili, N., Nazerian, Z., Muhammadnajad, A., Yadegari, F., Reza Esmailinejad, M., & Farahmand, L. (2023). Production of novel recombinant anti-EpCAM antibody as targeted therapy for breast cancer. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2023.110656
Vancouver
Mirzaei R, Shafiee S, Vafaei R, Salehi M, Jalili N, Nazerian Z, et al. Production of novel recombinant anti-EpCAM antibody as targeted therapy for breast cancer. International Immunopharmacology. 2023. doi:10.1016/j.intimp.2023.110656
BibTeX
@article{Mirzaei2023,
author = {Mirzaei, Roya and Shafiee, Soodabeh and Vafaei, Rana and Salehi, Malihe and Jalili, Neda and Nazerian, Zahra and Muhammadnajad, Ahad and Yadegari, Fatemeh and Reza Esmailinejad, Mohamad and Farahmand, Leila},
title = {Production of novel recombinant anti-EpCAM antibody as targeted therapy for breast cancer},
journal = {International Immunopharmacology},
year = {2023},
doi = {10.1016/j.intimp.2023.110656}
}
EUVIMED